Jury still out on Avastin as standard in ovarian cancer
This article was originally published in Scrip
Executive Summary
Roche's Avastin (bevacizumab) has improved median progression-free survival (PFS) by close to four months in its first Phase III first-line trial in advanced ovarian cancer, but overall survival data from this trial and another ongoing study may be needed before experts decide that it is the new standard of care in the disease when used in combination with chemotherapy.